双打击基因表达特征定义生发中心B细胞样弥漫大B细胞淋巴瘤的独特亚群
研究对157例原发生发中心B细胞样弥漫大B细胞淋巴瘤(GCB-DLBCL)进行RNA测序,建立104基因双打击特征(DHITsig),将27%的GCB-DLBCL归为DHITsig阳性,其中仅一半携带MYC和BCL2重排。DHITsig阳性患者接受R-CHOP免疫化疗后结局较差(5年至进展率57%对81%,P<.001),该预后价值在独立验证队列中得到证实,并转化为可应用于常规活检样本的NanoString检测(DLBCL90)。
要点
- 104基因DHITsig将27%的GCB-DLBCL归为阳性,仅半数携带MYC和BCL2重排。
- DHITsig阳性患者R-CHOP后5年至进展率57%对81%(P<.001),不依赖HGBL-DH/TH-BCL2状态。
- NanoString DLBCL90检测可复现RNA测序的预后分层。
核心结论
- 在GCB-DLBCL中定义了一个以HGBL-DH/TH-BCL2基因表达特征为标志的临床和生物学独特亚群,并转化为可应用于常规活检样本的检测,以探索其指导患者管理的效用。
研究设计与样本
- 分析157例原发GCB-DLBCL(含25例HGBL-DH/TH-BCL2)的RNA测序数据以定义基因表达特征,并结合靶向重测序、全外显子测序、RNA测序和免疫组化数据评估相关特征。
主要发现
- 104基因双打击特征(DHITsig)将27%的GCB-DLBCL归为DHITsig阳性组,其中仅一半携带MYC和BCL2重排(HGBL-DH/TH-BCL2)。
- DHITsig阳性患者接受利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松免疫化疗后结局较DHITsig阴性患者差(5年至进展率57%对81%,P<.001),与HGBL-DH/TH-BCL2状态无关。
- DHITsig的预后价值在独立验证队列中得到证实。
- DHITsig阳性肿瘤的生物学特征为推测的非亮区生发中心细胞起源和包含染色质修饰相关基因的独特突变图谱。
- 新的NanoString检测(DLBCL90)复现了RNA测序的预后意义和分组。
关键数值与推荐
- DHITsig阳性组5年至进展率为57%,DHITsig阴性组为81%(P<.001)。
- DHITsig将27%的GCB-DLBCL归为阳性组,其中仅一半携带MYC和BCL2重排。
- DHITsig阳性转化的滤泡性淋巴瘤25例中11例为HGBL-DH/TH-BCL2,DHITsig阴性组50例中为零。
临床怎么用
- DHITsig已转化为NanoString DLBCL90检测,可应用于常规可及的活检样本,以探索其指导患者管理的效用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. PATIENTS AND METHODS: We analyzed RNA sequencing data from 157 de novo germinal center B-cell-like (GCB)-DLBCLs, including 25 with HGBL-DH/TH- BCL2, to define a gene expression signature that distinguishes HGBL-DH/TH- BCL2 from other GCB-DLBCLs. To assess the genetic, molecular, and phenotypic features associated with this signature, we analyzed targeted resequencing, whole-exome sequencing, RNA sequencing, and immunohistochemistry data. RESULTS: We developed a 104-gene double-hit signature (DHITsig) that assigned 27% of GCB-DLBCLs to the DHITsig-positive group, with only one half harboring MYC and BCL2 rearrangements (HGBL-DH/TH- BCL2). DHITsig-positive patients had inferior outcomes after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy compared with DHITsig-negative patients (5-year time to progression rate, 57% and 81%, respectively; P < .001), irrespective of HGBL-DH/TH- BCL2 status. The prognostic value of DHITsig was confirmed in an independent validation cohort. DHITsig-positive tumors are biologically characterized by a putative non-light zone germinal center cell of origin and a distinct mutational landscape that comprises genes associated with chromatin modification. A new NanoString assay (DLBCL90) recapitulated the prognostic significance and RNA sequencing assignments. Validating the association with HGBL-DH/TH- BCL2, 11 of 25 DHITsig-positive-transformed follicular lymphomas were classified as HGBL-DH/TH- BCL2 compared with zero of 50 in the DHITsig-negative group. Furthermore, the DHITsig was shared with the majority of B-cell lymphomas with high-grade morphology tested. CONCLUSION: We have defined a clinically and biologically distinct subgroup of tumors within GCB-DLBCL characterized by a gene expression signature of HGBL-DH/TH- BCL2. This knowledge has been translated into an assay applicable to routinely available biopsy samples, which enables exploration of its utility to guide patient management.
引用
- Ennishi D, Jiang A, Boyle M, et al. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018. PMID: 30523716. doi:10.1200/JCO.18.01583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。